Jazz Pharmaceuticals PLC (JAZZ)

107.34 +1.79  +1.70% NASDAQ Jul 14, 16:59 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
08/06/2020 16:30 EDT Misc Jazz Pharmaceuticals PLC Second Quarter Earnings Conference Call in 2020
08/06/2020 Earnings Jazz Pharmaceuticals PLC Second Quarter Earnings in 2020 Release
07/30/2020 Misc Jazz Pharmaceuticals PLC Annual General Meeting for 2019
05/05/2020 16:30 EDT Misc Jazz Pharmaceuticals PLC First Quarter Earnings Conference Call for 2020
05/05/2020 Earnings Jazz Pharmaceuticals PLC First Quarter Earnings Result for 2020
02/25/2020 16:30 EST Misc Jazz Pharmaceuticals PLC Fourth Quarter Earnings Conference Call for 2019
02/25/2020 Earnings Jazz Pharmaceuticals PLC Fourth Quarter Earnings in 2019 Release
02/25/2020 Misc Jazz Pharmaceuticals PLC Annual Report for 2019
11/05/2019 16:30 EST Misc Jazz Pharmaceuticals PLC Third Quarter Earnings Conference Call for 2019
11/05/2019 Earnings Jazz Pharmaceuticals PLC Third Quarter Earnings in 2019 Release
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.jazzpharmaceuticals.com
  • Investor Relations URL: http://investor.jazzpharma.com/phoenix.zhtml?c=210227&p=irol-irhome
  • HQ State/Province: N/A
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Value
  • Next Earnings Release: Aug. 06, 2020
  • Last Earnings Release: May. 05, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and indications in neuroscience and hematology-oncology. Jazz's product portfolio includes its lead drug, Xyrem, for narcolepsy, Sunosi for improving wakefulness in patients with excessive daytime sleepiness, Defitelio for severe veno-occlusive disease after stem cell transplant, Vyxeos for acute myeloid leukemia, and Zepzelca for small cell lung cancer.

Top Fund Holders

Symbol Name Weighting
PVSBX Putnam Capital Spectrum B 9.95%
PYSRX Putnam Equity Spectrum R 9.61%
XPH SPDR® S&P Pharmaceuticals ETF 4.33%
FTXH First Trust Nasdaq Pharmaceuticals ETF 3.57%
PILL Direxion Daily Phrmctcl&MdclBl3XShrsETF 2.70%
IHE iShares US Pharmaceuticals ETF 2.69%
PPH VanEck Vectors Pharmaceutical ETF 2.67%
HNTVX Heartland Value Institutional 2.44%
RBF1092 RBC U.S. Mid-Cap Value Equity Fund D 2.19%
FMPTX Fidelity Advisor® Mid Cap Value M 1.65%
HRMVX Harbor Mid Cap Value Admin 1.41%
JSMD Janus Henderson Small/Md Cp Gr Alpha ETF 1.41%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.